ACUT
AccuStem Sciences, Inc.0.7000
-0.0500-6.67%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
11.25MP/E (TTM)
-Basic EPS (TTM)
-0.11Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q2 FY2025 results
AccuStem Sciences posted a Q2 net loss of $401,403, up 44% year-over-year from $278,225, driven by higher research and development costs for patent work and lab consulting, while general and administrative expenses climbed 44% on payroll from added headcount. For the half-year, the net loss widened 5% to $841,811, with R&D up 36% but G&A steady at 2% growth. Cash burn eased to $268,615 from operations, thanks to related-party advances boosting the balance to $31,341, yet liquidity strains persist amid a $2.5 million working capital deficit. Stock issuance added nearly 4 million shares, diluting ownership but funding progress toward MSC and StemPrintER launches. No revenue yet, but validation data strengthens the path. Internal controls faltered on resource gaps. Competition from larger diagnostics firms looms large.
10-Q
Q1 FY2025 results
AccuStem Sciences narrowed its Q1 FY2025 net loss to $440k from $527k a year earlier, trimming operating expenses 16% y/y to $440k while R&D ticked up 22% to $28k on lab and consulting work. General and administrative costs dropped 18% to $412k, thanks to leaner headcount, yet the firm issued nearly 4 million new shares for $1.6M in funding to bolster its $36k cash pile and $1.5M advance for an intangible asset. No revenue yet, but the team pushes toward 2026 launches of MSC lung nodule tests and StemPrintER breast cancer assays under CLIA rules. Cash burn persists; related-party advances keep it afloat. Competition from bigger diagnostics players looms large.
10-K
FY2024 results
AccuStem Sciences reported a narrowed net loss of $1.5 million for FY2024 ended December 31, 2024, down 27% from $2.1 million in 2023, driven by reduced general and administrative expenses amid ongoing clinical development of its MSC and StemPrintER genomic tests. With no revenue yet, the company advanced key milestones, including a partnership with EmeritusDx for lab processing and transfer of assays, positioning for CLIA certification and U.S. launch within 12 months; Q4 saw steady R&D spend of $138K annually, reflecting sequential stability in preclinical validation efforts without quarterly breakdowns disclosed. Liquidity remains tight at $5K cash, supported by $781K in related-party advances, while $3.4M in payables highlight funding needs for commercialization. No annual guidance issued, but management eyes $6.3B U.S. market potential. Ongoing net losses raise going-concern doubts, potentially stalling test launches if financing falters.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ADVB
Advanced Biomed Inc.
0.39-0.00
APDN
Applied DNA Sciences, Inc.
5.62+1.35
BIAF
bioAffinity Technologies, Inc.
1.38-0.10
CSTL
Castle Biosciences, Inc.
39.05+0.17
EXAS
Exact Sciences Corporation
101.76+0.02
NSTM
NovelStem International Corp.
0.02+0.00
PRPO
Precipio, Inc.
24.02-0.04
VCYT
Veracyte, Inc.
43.22-0.31
YDES
YD Bio Limited
12.62+0.22